title: Effect of angiotensin blockade on the association between albuminuria and peripheral arterial disease in elderly Taiwanese patients with type 2 diabetes mellitus.
abstract: BACKGROUND
  The aim of the present study was to examine the impact of the clinical use of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) on the association between the urinary albumin/creatinine ratio (ACR) and ankle-brachial index (ABI) or peripheral arterial disease (PAD) in elderly Taiwanese patients with type 2 diabetes mellitus.
  
  
  RESULTS
  Two-hundred and ninety patients (108 men, 182 women) aged > or = 65 years (mean +/- SD, 71.6 +/-4.9) were cross-sectionally studied. ACR was expressed as the natural logarithm [ln(ACR)] and divided into normoalbuminuria (< 30.0 microg/mg) and albuminuria (> or = 30.0 microg/mg). ABI was evaluated both continuously and as peripheral arterial disease (PAD) (-) and PAD (+) using the cutoff of 0.9. Statistical analyses were performed with consideration of covariates and the use of ACEI/ARB. Results showed that in patients not using ACEI/ARB, ln (ACR) negatively correlated with ABI (r = -0.261, p < 0.01) and was associated with ABI with adjusted regression coefficient of -0.0213 (p < 0.05). PAD patients had a significantly higher level of ln (ACR) than those without PAD (4.83+/-1.34 vs 3.73+/-1.29, p < 0.001) and PAD prevalence was significantly higher in those with albuminuria than in those with normoalbuminuria (22.6% vs 4.9%, p < 0.001). The multivariate-adjusted odds ratio for PAD for every 1 unit increment of ln (ACR) was 2.10 (1.31-3.38), and for albuminuria vs normoalbuminuria 3.86 (1.04-14.31) in patients not using ACEI/ARB. In patients using ACEI/ARB, none of these analyses was significant. Patients using ACEI/ARB had a significantly lower risk of PAD with a multivariate-adjusted odds ratio of 0.34 (0.12-0.97).
  
  
  CONCLUSIONS
  ACR negatively correlates with ABI and is associated with PAD in elderly diabetic patients not treated with ACEI/ARB. The use of ACEI/ARB attenuates this association and may be associated with a lower risk of PAD.
authors.affiliation: Division of Endocrinology and Metabolism, National Taiwan University Hospital, Taipei, Taiwan. ccktsh@ms6.hinet.net
authors.forename: Chin-Hsiao
authors.initials: CH
authors.lastname: Tseng
authors.forename: Ching-Ping
authors.initials: CP
authors.lastname: Tseng
authors.forename: Tong-Yuan
authors.initials: TY
authors.lastname: Tai
authors.forename: Choon-Khim
authors.initials: CK
authors.lastname: Chong
mesh_terms: D000368:Aged; D000418:Albumins / Q000032:analysis; D000419:Albuminuria / Q000150:complications / Q000188:drug therapy / Q000652:urine*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D015415:Biomarkers / Q000652:urine; D003401:Creatine / Q000652:urine; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy / Q000652:urine*; D003925:Diabetic Angiopathies / Q000150:complications / Q000188:drug therapy / Q000652:urine*; D005260:Female; D006801:Humans; D008297:Male; D016491:Peripheral Vascular Diseases / Q000145:classification / Q000188:drug therapy / Q000652:urine*; D012307:Risk Factors; D013624:Taiwan
chemical_list: D000418:Albumins; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D015415:Biomarkers; D003401:Creatine